At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 371 enrolled
Drug / intervention
Secukinumab (75 mg) +2 moredrug
Likely dose
Secukinumab (75 mg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the 16 Week Efficacy and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis
In Brief
A Phase 3 clinical trial evaluating Secukinumab (75 mg), Secukinumab (150 mg), and 1 other intervention for Ankylosing Spondylitis. Completed, enrolled 371 participants across 67 sites in 14 countries.
Detailed Summary
This study will assess the efficacy and safety of secukinumab in patients with active ankylosing spondylitis who are intolerant to or have had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnkylosing Spondylitis
CountriesBelgium, Bulgaria, Canada, France, Germany, Italy, Mexico, Netherlands, Peru, Russia, Taiwan, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2011
Enrollment StartOct 2011
Primary CompletionDec 2014
TodayJul 2026
First PostedMay 23, 2011
Enrollment StartOct 1, 2011
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 15.1 years ago
Interventions
Secukinumab (75 mg)drug
Secukinumab (75 mg)
Secukinumab (150 mg)drug
Secukinumab (150 mg)
Placebodrug
Placebo